Lixadesiran + pixofisiran is under clinical development by Sirnaomics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase II drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lixadesiran + pixofisiran’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lixadesiran + pixofisiran overview
STP705 is under development for the treatment of cutaneous squamous cell carcinoma in situ (isSCC, Bowen's disease), metastatic liver cancer, facial squamous cell skin cancer in situ (isSCC), basal cell carcinoma, primary sclerosing cholangitis, keloid scar less healing, skin hypertrophic scars, abdominal obesity. The drug is a siRNA and is administered through intradermal injection, topically as cream, intra-tumorally and subcutaneously. Drug has two small interfering RNAs (pixofisiran INN and lixadesiran INN) that target TGF-beta 1 and COX-2, respectively and is being developed based on PNP platform.
It was under development for the treatment of pulmonary fibrosis, kidney fibrosis, wounds, pancreatic cancer, non-alcoholic steatohepatitis, cholangiocarcinoma, hepatocellular carcinoma and bladder cancer.
Sirnaomics overview
Sirnaomics, is a healthcare service provider that discovers and develops therapeutics. The company’s pipeline products include STP705 treats cutaneous squamous cell carcinoma (IssCC) and basal cell carcinoma (BCC) ;STP707 targets multiple solid tumors; STP705 is for the treatment of fat remodeling; RV-1730 for covid 19; STP122G treats anticoagulation/thrombosis; STP125G targets hypertriglyceridemia; STP144G is for the treatment of complement mediated diseases. Sirnaomics offers product development, preclinical programs, clinical development services, among others. It has its presence in the US and China. Sirnaomics company is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of Lixadesiran + pixofisiran’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
